A Novel Anti-EGFR mAb Ame55 with Lower Toxicity and Better Efficacy than Cetuximab When Combined with Irinotecan. (13th January 2019)

• Record Type: Journal Article
• Authors: Qiu, Weiyi; Zhang, Chang; Wang, Shuang; Yu, Xiaoyan; Wang, Qiong; Zeng, Dadi; Du, Peng; Ma, Jinling; Zheng, Yiqiong; Pang, Bo; Yu, Yunzhou; Long, Feng; Pang, Xiaobin; Sun, Zhiwei
• Other Names: Xu Liang Guest Editor.
• Is Part Of: Journal of immunology research. Volume 2019(2019)
• Publication Date: 2019-01-13
• Subjects: Immunology -- Periodicals; Immunology -- Research -- Periodicals; 616.07905
• DOI: 10.1155/2019/3017360
• Languages: English
• ISSNs: 2314-8861

Abstract

Abstract : To improve efficacy and minimize toxicity of EGFR inhibition treatment, we developed Ame55, a novel anti-EGFR IgG1 with lower affinity to EGFR than cetuximab (C225) from a human phage library. Ame55 had lower bioactivity than cetuximab in vitro but similar antitumor efficacy as cetuximab in vivo . Moreover, Ame55 was more efficacious than cetuximab in a Lovo cell xenograft tumor model when combined with irinotecan (CPT-11). Ame55 concentrates in the mouse xenograft tumor and has less toxicity than cetuximab in cynomolgus monkeys in an overdose study.